Prostate cancer

Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
Wendy Mao, Ali Ghasemzadeh, Zachary T. Freeman, Aleksandar Obradovic, Matthew G. Chaimowitz, Thomas R. Nirschl, Emily McKiernan, Srinivasan Yegnasubramanian, Charles G. Drake

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 277; DOI: 10.1186/s40425-019-0758-y
CAR-T cell therapy: a potential new strategy against prostate cancer
Giuseppe Schepisi, Maria Concetta Cursano, Chiara Casadei, Cecilia Menna, Amelia Altavilla, Cristian Lolli, Claudio Cerchione, Giovanni Paganelli, Daniele Santini, Giuseppe Tonini, Giovanni Martinelli, Ugo De Giorgi

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 258; DOI: 10.1186/s40425-019-0741-7
Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab
Hao Chi Zhang, Wenyi Luo, Yinghong Wang

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 47; DOI: 10.1186/s40425-019-0532-1
FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab
Matthew Scarpelli, Christopher Zahm, Scott Perlman, Douglas G. McNeel, Robert Jeraj, Glenn Liu

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 23; DOI: 10.1186/s40425-019-0516-1
1-Pyrroline-5-carboxylate released by prostate Cancer cell inhibit T cell proliferation and function by targeting SHP1/cytochrome c oxidoreductase/ROS Axis
Yutao Yan, Lei Chang, Hongzhe Tian, Lu Wang, Yawei Zhang, Tao Yang, Guohao Li, Weifeng Hu, Kavita Shah, Gang Chen, Yonglian Guo

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 148; DOI: 10.1186/s40425-018-0466-z
Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine
Ellen Wargowski, Laura E. Johnson, Jens C. Eickhoff, Lauren Delmastro, Mary Jane Staab, Glenn Liu, Douglas G. McNeel

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 21; DOI: 10.1186/s40425-018-0333-y
Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination
Laura E. Johnson, Brian M. Olson, Douglas G. McNeel

Journal for ImmunoTherapy of Cancer Dec 2017, 5 (1) 56; DOI: 10.1186/s40425-017-0260-3
Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulation
Mohanad H. Nada, Hong Wang, Grefachew Workalemahu, Yoshimasa Tanaka, Craig T. Morita

Journal for ImmunoTherapy of Cancer Dec 2017, 5 (1) 9; DOI: 10.1186/s40425-017-0209-6
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma
Douglas G. McNeel, Neil H. Bander, Tomasz M. Beer, Charles G. Drake, Lawrence Fong, Stacey Harrelson, Philip W. Kantoff, Ravi A. Madan, William K. Oh, David J. Peace, Daniel P. Petrylak, Hank Porterfield, Oliver Sartor, Neal D. Shore, Susan F. Slovin, Mark N. Stein, Johannes Vieweg, James L. Gulley

Journal for ImmunoTherapy of Cancer Dec 2016, 4 (1) 92; DOI: 10.1186/s40425-016-0198-x
Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide
Ioannis F. Voutsas, Eleftheria A. Anastasopoulou, Panagiotis Tzonis, Michael Papamichail, Sonia A. Perez, Constantin N. Baxevanis

Journal for ImmunoTherapy of Cancer Dec 2016, 4 (1) 75; DOI: 10.1186/s40425-016-0183-4

Main menu

Prostate cancer

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Prostate cancer

Pages